Karyopharm Therapeutics Inc. (KPTI)

NMS – Real Time Price. Currency in USD

8.91

+0.10 (1.19%)

At close: May 12, 2026, 4:00 PM EDT

9.09

+0.18 (1.96%)

Pre-market: May 13, 2026, 8:20 AM EDT

12.05.2026

Karyopharm to Participate at Upcoming Investor Conferences

NEWTON, Mass., May 12, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in May: H.C.

07.05.2026

Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026

-- Conference Call Scheduled for Thursday, May 14, 2026, at 8:00 a.m. ET -- NEWTON, Mass.

21.04.2026

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting

NEWTON, Mass., April 21, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its late-breaking abstract was accepted for an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 to June 2 in Chicago.

27.03.2026

Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?

Karyopharm Therapeutics (KPTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

26.03.2026

Karyopharm: Putting The Phase 3 Trial In Context

Karyopharm Therapeutics faces heightened uncertainty after mixed phase 3 SENTRY results for selinexor in myelofibrosis. KPTI met the spleen volume reduction endpoint but missed symptom improvement, while showing a promising, though immature, overall survival signal. Dire cash position persists despite a $30 million private placement; runway extends only into Q2 2026, with existential funding risks looming.

25.03.2026

KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data

Karyopharm Therapeutics stock sinks 18% after mixed phase III data show spleen benefit but no symptom edge for selinexor combo in myelofibrosis, raising questions on efficacy.

24.03.2026

Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis Transcript

Videos

No Data

There is no data to display

Press releases

21.04.2026

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting

24.03.2026

Karyopharm Announces $30 Million Private Placement with RA Capital

NEWTON, Mass., March 24, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a securities purchase agreement with RA Capital Management for a private placement that is expected to result in gross proceeds of approximately $30 million before deducting placement agent fees and offering expenses, and an additional approximately $44 million of gross proceeds if the accompanying warrants are exercised in full.

24.03.2026

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction

– While Similar Symptom Improvement Was Observed Across the Two Arms Relative to Baseline, SENTRY Did Not Meet its Second Co-Primary Endpoint of Abs-TSS – – SENTRY Demonstrated a Rapid and Near Doubling of Patients Achieving SVR35 at Week 24, versus Ruxolitinib – – Promising Overall Survival Signal with >50% Reduction of Risk of Death versus Ruxolitinib – – Evidence of Potential Disease Modification with More Patients Achieving ≥20% Reductions in VAF as Early as Week 24 versus Ruxolitinib – – No New Safety Signals Identified – – Karyopharm will Meet with the FDA to Discuss the Totality of the Data and Potential sNDA Filing – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass.

02.03.2026

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., March 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,450 restricted stock units (RSUs) to two newly-hired employees.

Karyopharm Therapeutics Inc. (KPTI)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Karyopharm Therapeutics Inc. (KPTI)

Karyopharm to Participate at Upcoming Investor Conferences

Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting

Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?

Karyopharm: Putting The Phase 3 Trial In Context

KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data

Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis Transcript

Videos

No Data

Press releases

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting

Karyopharm Announces $30 Million Private Placement with RA Capital

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm to Participate at Upcoming Investor Conferences

Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting

Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?

Karyopharm: Putting The Phase 3 Trial In Context

KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data

Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis Transcript

Videos

No Data

Press releases

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting

Karyopharm Announces $30 Million Private Placement with RA Capital

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Search stocks

Karyopharm Therapeutics Inc. (KPTI)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Karyopharm Therapeutics Inc. (KPTI)

Karyopharm to Participate at Upcoming Investor Conferences

Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting

Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?

Karyopharm: Putting The Phase 3 Trial In Context

KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data

Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis Transcript

Videos

No Data

Press releases

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting

Karyopharm Announces $30 Million Private Placement with RA Capital

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm to Participate at Upcoming Investor Conferences

Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting

Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?

Karyopharm: Putting The Phase 3 Trial In Context

KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data

Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis Transcript

Videos

No Data

Press releases

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting

Karyopharm Announces $30 Million Private Placement with RA Capital

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)